Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.60 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.60 |
| ▸ | BRS3 | P32247 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.60 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.60 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.60 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.60 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.60 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.60 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.60 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.60 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.60 |
| ▸ | WDR5 | P61964 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.60 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omeprazole SCHEMBL1192 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29772327 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL19535 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL30426884 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL140006 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL28256108 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL29691369 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2516731 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL6758624 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL6320176 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4690246-A1 | TUNING A BIOLOGICAL NETWORK MODEL | Charité - Universitätsmedizin Berlin (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-3776600-B1 | NEUTRON IMAGING SYSTEMS AND METHODS | PHOENIX LLC (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2025128821-A1 | COMPOSITIONS AND METHODS FOR ADP-RIBOSYLATION FACTOR MOLECULAR TRAFFICKING | JUVENA THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025051281-A1 | BREXPIPRAZOLE GEL FOR INJECTION | 广州玻思韬控释药业有限公司 | 2025-03-13 | — | — | WO | claimed |
| WO-2025054401-A2 | CAP ANALOGS AND METHODS OF USE THEREOF | TRILINK BIOTECHNOLOGIES, LLC (US) | 2025-03-13 | — | — | WO | claimed |
| WO-2025024320-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | REGENCOR, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-119137160-A | Nucleic acid vaccine for Respiratory Syncytial Virus (RSV) | 苏州艾博生物科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| EP-4469465-A1 | TRINUCLEOTIDE CAP ANALOGS AND METHODS OF USE THEREOF | TriLink BioTechnologies, LLC (US) | 2024-12-04 | — | — | EP | claimed |
| CN-118858483-A | Method for detecting related substances of epinastine intermediate 4-piperazinyl benzothiophene hydrochloride | 万特制药(海南)有限公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2024208887-A1 | TUNING A BIOLOGICAL NETWORK MODEL | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2024-10-10 | — | — | WO | claimed |
| WO-2024179559-A1 | NUCLEIC ACID VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-09-06 | — | — | WO | claimed |
| CN-118440856-A | Bacillus subtilis and application thereof in fermentation of traditional Chinese medicine | 河南农业大学 | 2024-08-06 | — | — | CN | claimed |
| US-20240230568-A1 | EMBEDDED SENSOR SYSTEM FOR MEASUREMENT AND MONITORING OF THE PORE SOLUTION ELECTRICAL RESISTIVITY IN CONCRETE MATERIALS AND STRUCTURES | PENN STATE RES FOUND (US) | 2024-07-11 | — | — | US | claimed |
| EP-3820512-B1 | IMMUNOMODULATING COMPOSITIONS COMPRISING OLIGOSACCHARIDE DERIVATIVES | AYUVIS RES INC (US) | 2024-04-24 | — | — | EP | claimed |
| CN-117599000-A | Polyphenol nanoparticle, preparation method thereof, and application of polyphenol nanoparticle preparation in cerebral apoplexy treatment | 中国科学院长春应用化学研究所 | 2024-02-27 | — | — | CN | claimed |
| WO-2023147352-A1 | TRINUCLEOTIDE CAP ANALOGS AND METHODS OF USE THEREOF | TRILINK BIOTECHNOLOGIES, LLC (US) | 2023-08-03 | — | — | WO | claimed |
| US-20230033582-A1 | POLYMERIC NANOPARTICLES FOR ENHANCED CANCER TREATMENT | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2023-02-02 | — | — | US | claimed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | claimed |
| WO-2022048795-A1 | METHOD FOR PRODUCING A GREEN PAPER FOR PRODUCING A GAS DIFFUSION LAYER FOR A FUEL CELL | GIESECKE+DEVRIENT CURRENCY TECHNOLOGY GMBH (DE) | 2022-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | ATP4A 2349/4885ATP4B 2285/4885BRS3 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.